Evotec to Strengthen its Compound Collection through a Collaboration with ChemBridge
Evotec AG announced that it has entered into a collaboration with ChemBridge, to further enhance its screening library. Evotec's library of 250,000 drug-like and lead-like compounds is available to clients for screening. Through this collaboration, Evotec will increase its high throughput screening collection through the addition of initially 110,000 diverse and lead-like compounds from the ChemBridge Library Collection. These new compounds complement the chemical diversity of Evotec's existing collection and will further enhance the quality of the hits provided to our partners.
Dr Mario Polywka, Chief Operating Officer at Evotec stated: "We are happy to partner with ChemBridge on the expansion of Evotec's high throughput screening collection. This collaboration coupled with our continued investment in our world leading, hit-identification platform will allow Evotec to maintain our market leadership and continue to provide high quality hit compounds to our clients."
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.